SUBSCRIBE
SUBSCRIBE

Apnimed

20 Holyoke Street Cambridge MA 02138 US
Visit website
Email Us
  • Featured Employer
JOBS
IN THE PRESS
Genetown
Apnimed to Present at the Jefferies Healthcare Conference
June 6, 2022
 · 
2 min read
Genetown
Apnimed Announces $62.5 Million Series C Financing to Advance Development of Novel Pharmaceutical Treatments for Obstructive Sleep Apnea (OSA) and Related Sleep Disorders
May 4, 2022
 · 
5 min read
Genetown
Apnimed to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 5, 2022
 · 
2 min read
Genetown
Apnimed to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 10, 2022
 · 
2 min read
Genetown
Apnimed Study APC-004 Phase 2 Data to be Presented at World Sleep 2022
March 9, 2022
 · 
4 min read
Genetown
Apnimed to Participate in the SVB Leerink Global Healthcare Conference
February 7, 2022
 · 
2 min read
Genetown
Apnimed to Present at the 40th Annual JP Morgan Healthcare Conference
January 6, 2022
 · 
2 min read
Drug Development
Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)
December 16, 2021
 · 
5 min read
Drug Development
Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Investigational Treatment for the Disease
October 13, 2021
 · 
6 min read
Drug Development
Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment
October 13, 2021
 · 
7 min read
Load More